Capsule

CAUTIONARY AND ADVISORY LABELS 3, 5, 8, 25

- **Gabapentin (Non-proprietary)**
  Gabapentin 100 mg Gabapentin 100mg capsules | 100 capsule PoM £18.29 DT = £1.81 CD3
  Gabapentin 300 mg Gabapentin 300mg capsules | 100 capsule PoM £42.40 DT = £3.15 CD3
  Gabapentin 400 mg Gabapentin 400mg capsules | 100 capsule PoM £49.06 DT = £3.86 CD3
- **Neurontin** (Pfizer Ltd)
  Gabapentin 100 mg Neurontin 100mg capsules | 100 capsule PoM £18.29 DT = £1.81 CD3
  Gabapentin 300 mg Neurontin 300mg capsules | 100 capsule PoM £42.40 DT = £3.15 CD3
  Gabapentin 400 mg Neurontin 400mg capsules | 100 capsule PoM £49.06 DT = £3.86 CD3

Lacosamide

22-Feb-2018

- **INDICATIONS AND DOSE**

Monotherapy of focal seizures with or without secondary generalisation

- BY MOUTH, OR BY INTRAVENOUS INFUSION
- Child (body-weight 50 kg and above): Initially 50 mg twice daily, then increased to 100 mg twice daily, after one week, alternatively initially 100 mg twice daily; increased in steps of 50 mg twice daily (max. per dose 300 mg twice daily) if necessary and if tolerated, dose to be increased at weekly intervals
- Child 4–17 years (body-weight up to 50 kg): (consult product literature)

Monotherapy of focal seizures with or without secondary generalisation (alternative loading dose regimen when it is necessary to rapidly attain therapeutic plasma concentrations) (under close medical supervision)

- BY MOUTH, OR BY INTRAVENOUS INFUSION
- Child (body-weight 50 kg and above): Loading dose 200 mg, followed by 100 mg twice daily, to be given 12 hours after initial dose; increased in steps of 50 mg twice daily (max. per dose 300 mg twice daily) if necessary and if tolerated, dose to be increased at weekly intervals

Adjunctive treatment of focal seizures with or without secondary generalisation

- BY MOUTH, OR BY INTRAVENOUS INFUSION
- Child (body-weight 50 kg and above): Initially 50 mg twice daily, then increased to 100 mg twice daily, after one week; increased in steps of 50 mg twice daily (max. per dose 200 mg twice daily) if necessary and if tolerated, dose to be increased at weekly intervals
- Child 4–17 years (body-weight up to 50 kg): (consult product literature)

Adjunctive treatment of focal seizures with or without secondary generalisation (alternative loading dose regimen when it is necessary to rapidly attain therapeutic plasma concentrations) (under close medical supervision)

- BY MOUTH, OR BY INTRAVENOUS INFUSION
- Child (body-weight 50 kg and above): Loading dose 200 mg, followed by 100 mg twice daily, to be given 12 hours after initial dose; increased in steps of 50 mg twice daily (max. per dose 200 mg twice daily) if necessary and if tolerated, dose to be increased at weekly intervals

- **CONTRA-INDICATIONS** Second- or third-degree AV block
- **CAUTIONS** Conduction problems · risk of PR-interval prolongation · severe cardiac disease
- **INTERACTIONS** → Appendix 1: antiepileptics
- **SIDE-EFFECTS**
  - **Common or very common** Asthenia · concentration impaired · confusion · constipation · depression · diarrhoea · dizziness · drowsiness · dry mouth · dysarthria · dyspepsia · flatulence · gait abnormal · headache · insomnia · mood altered · movement disorders · muscle spasms · nausea · nystagmus · sensation abnormal · skin reactions · tinnitus · vertigo · vision disorders · vomiting
  - **Uncommon** Aggression · agitation · angioedema · arrhythmias · atrioventricular block · hallucination · psychotic disorder · suicidal tendencies · syncope
  - **Frequency not known** Agranulocytosis
- **ALLERGY AND CROSS-SENSITIVITY** Antiepileptic hypersensitivity syndrome associated with lacosamide. See under Epilepsy p. 195 for more information.
- **PREGNANCY** See also *Pregnancy* in Epilepsy p. 195.
  Monitoring The dose should be monitored carefully during pregnancy and after birth, and adjustments made on a clinical basis.
- **BREAST FEEDING** Manufacturer advises avoid—present in milk in *animal* studies.
- **HEPATIC IMPAIRMENT** Manufacturer advises caution (risk of increased exposure), particularly in severe impairment (no information available).
  Dose adjustments Manufacturer advises consider dose reduction—consult product literature.
- **RENAL IMPAIRMENT** Consult product literature.
- **DIRECTIONS FOR ADMINISTRATION**
  - With intravenous use For *intermittent intravenous infusion*, manufacturer advises give undiluted or dilute with Glucose 5% *or* Sodium Chloride 0.9% *or* Lactated Ringer's Solution; give over 15–60 minutes—give doses greater than 200 mg over at least 30 minutes.
- **PRESCRIBING AND DISPENSING INFORMATION** Flavours of syrup may include strawberry.
- **PATIENT AND CARER ADVICE**
  Medicines for Children leaflet: Lacosamide for preventing seizures www.medicinesforchildren.org.uk/lacosamide-preventing-seizures
- **NATIONAL FUNDING/ACCESS DECISIONS**

Scottish Medicines Consortium (SMC) decisions

SMC No. 532/09

The *Scottish Medicines Consortium* has advised (February 2009) that lacosamide (*Vimpat*®) is accepted for restricted use within NHS Scotland as adjunctive treatment for focal seizures with or without secondary generalisation in patients from 16 years. It is restricted for specialist use in refractory epilepsy.

SMC No. 1301/18

The *Scottish Medicines Consortium* has advised (February 2018) that lacosamide (*Vimpat*®) is accepted for restricted use within NHS Scotland as adjunctive treatment for focal seizures with or without secondary generalisation in adolescents and children from 4 years of age with epilepsy. It is restricted for specialist use in refractory epilepsy.

All Wales Medicines Strategy Group (AWMSG) decisions

AWMSG No. 3343

The *All Wales Medicines Strategy Group* has advised (March 2018) that lacosamide (*Vimpat*®) is recommended as an option for use within NHS Wales as adjunctive therapy in the treatment of focal seizures with or without secondary generalisation in children from 4 years of age up to 15 years of age with epilepsy.

- **MEDICINAL FORMS** There can be variation in the licensing of different medicines containing the same drug.

Solution for infusion

ELECTROLYTES: May contain Sodium

- **Vimpat** (UCB Pharma Ltd)
  Lacosamide 10 mg per 1 ml Vimpat 200mg/20ml solution for infusion vials | 1 vial PoM £29.70